nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoteridol—Generalised oedema—Thiotepa—sarcoma	0.0251	0.0251	CcSEcCtD
Gadoteridol—Abdominal cramps—Vincristine—sarcoma	0.0196	0.0196	CcSEcCtD
Gadoteridol—Injection site pain—Thiotepa—sarcoma	0.0183	0.0183	CcSEcCtD
Gadoteridol—Cyanosis—Etoposide—sarcoma	0.0151	0.0151	CcSEcCtD
Gadoteridol—Laryngospasm—Etoposide—sarcoma	0.0143	0.0143	CcSEcCtD
Gadoteridol—Fluid retention—Thiotepa—sarcoma	0.0142	0.0142	CcSEcCtD
Gadoteridol—Tingling sensation—Etoposide—sarcoma	0.0133	0.0133	CcSEcCtD
Gadoteridol—Apnoea—Etoposide—sarcoma	0.0126	0.0126	CcSEcCtD
Gadoteridol—Cardiovascular disorder—Etoposide—sarcoma	0.0122	0.0122	CcSEcCtD
Gadoteridol—Cardiac arrest—Thiotepa—sarcoma	0.0103	0.0103	CcSEcCtD
Gadoteridol—Generalised oedema—Epirubicin—sarcoma	0.0101	0.0101	CcSEcCtD
Gadoteridol—Rash maculo-papular—Etoposide—sarcoma	0.00974	0.00974	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Mitoxantrone—sarcoma	0.00966	0.00966	CcSEcCtD
Gadoteridol—Generalised oedema—Doxorubicin—sarcoma	0.00934	0.00934	CcSEcCtD
Gadoteridol—Dysphagia—Dactinomycin—sarcoma	0.00929	0.00929	CcSEcCtD
Gadoteridol—Cardiac arrest—Vincristine—sarcoma	0.00913	0.00913	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Etoposide—sarcoma	0.00803	0.00803	CcSEcCtD
Gadoteridol—Gingivitis—Epirubicin—sarcoma	0.00765	0.00765	CcSEcCtD
Gadoteridol—Cardiac arrest—Etoposide—sarcoma	0.00739	0.00739	CcSEcCtD
Gadoteridol—Injection site pain—Epirubicin—sarcoma	0.00736	0.00736	CcSEcCtD
Gadoteridol—Sweating—Vincristine—sarcoma	0.00709	0.00709	CcSEcCtD
Gadoteridol—Gingivitis—Doxorubicin—sarcoma	0.00708	0.00708	CcSEcCtD
Gadoteridol—Tinnitus—Thiotepa—sarcoma	0.00698	0.00698	CcSEcCtD
Gadoteridol—Sweating—Mitoxantrone—sarcoma	0.00691	0.00691	CcSEcCtD
Gadoteridol—Flushing—Dactinomycin—sarcoma	0.0069	0.0069	CcSEcCtD
Gadoteridol—Cardiovascular disorder—Epirubicin—sarcoma	0.00683	0.00683	CcSEcCtD
Gadoteridol—Injection site pain—Doxorubicin—sarcoma	0.00681	0.00681	CcSEcCtD
Gadoteridol—Dysphagia—Etoposide—sarcoma	0.00672	0.00672	CcSEcCtD
Gadoteridol—Bradycardia—Mitoxantrone—sarcoma	0.00658	0.00658	CcSEcCtD
Gadoteridol—Erythema—Thiotepa—sarcoma	0.00652	0.00652	CcSEcCtD
Gadoteridol—Lacrimation increased—Epirubicin—sarcoma	0.00652	0.00652	CcSEcCtD
Gadoteridol—Rhinitis—Mitoxantrone—sarcoma	0.00648	0.00648	CcSEcCtD
Gadoteridol—Erythema—Dactinomycin—sarcoma	0.00647	0.00647	CcSEcCtD
Gadoteridol—Cardiovascular disorder—Doxorubicin—sarcoma	0.00632	0.00632	CcSEcCtD
Gadoteridol—Lacrimation increased—Doxorubicin—sarcoma	0.00603	0.00603	CcSEcCtD
Gadoteridol—Ill-defined disorder—Dactinomycin—sarcoma	0.006	0.006	CcSEcCtD
Gadoteridol—Injection site reaction—Epirubicin—sarcoma	0.00597	0.00597	CcSEcCtD
Gadoteridol—Malaise—Dactinomycin—sarcoma	0.00584	0.00584	CcSEcCtD
Gadoteridol—Salivary hypersecretion—Epirubicin—sarcoma	0.00583	0.00583	CcSEcCtD
Gadoteridol—Fluid retention—Epirubicin—sarcoma	0.0057	0.0057	CcSEcCtD
Gadoteridol—Cough—Thiotepa—sarcoma	0.00569	0.00569	CcSEcCtD
Gadoteridol—Convulsion—Thiotepa—sarcoma	0.00565	0.00565	CcSEcCtD
Gadoteridol—Erythema—Mitoxantrone—sarcoma	0.00563	0.00563	CcSEcCtD
Gadoteridol—Hypertension—Thiotepa—sarcoma	0.00563	0.00563	CcSEcCtD
Gadoteridol—Anxiety—Thiotepa—sarcoma	0.00553	0.00553	CcSEcCtD
Gadoteridol—Injection site reaction—Doxorubicin—sarcoma	0.00552	0.00552	CcSEcCtD
Gadoteridol—Dysgeusia—Mitoxantrone—sarcoma	0.00551	0.00551	CcSEcCtD
Gadoteridol—Rash maculo-papular—Epirubicin—sarcoma	0.00546	0.00546	CcSEcCtD
Gadoteridol—Discomfort—Dactinomycin—sarcoma	0.00544	0.00544	CcSEcCtD
Gadoteridol—Salivary hypersecretion—Doxorubicin—sarcoma	0.0054	0.0054	CcSEcCtD
Gadoteridol—Oedema—Dactinomycin—sarcoma	0.00528	0.00528	CcSEcCtD
Gadoteridol—Fluid retention—Doxorubicin—sarcoma	0.00528	0.00528	CcSEcCtD
Gadoteridol—Ill-defined disorder—Mitoxantrone—sarcoma	0.00522	0.00522	CcSEcCtD
Gadoteridol—Malaise—Mitoxantrone—sarcoma	0.00508	0.00508	CcSEcCtD
Gadoteridol—Rash maculo-papular—Doxorubicin—sarcoma	0.00505	0.00505	CcSEcCtD
Gadoteridol—Convulsion—Vincristine—sarcoma	0.00501	0.00501	CcSEcCtD
Gadoteridol—Flushing—Etoposide—sarcoma	0.00499	0.00499	CcSEcCtD
Gadoteridol—Hypertension—Vincristine—sarcoma	0.00499	0.00499	CcSEcCtD
Gadoteridol—Cough—Mitoxantrone—sarcoma	0.00491	0.00491	CcSEcCtD
Gadoteridol—Convulsion—Mitoxantrone—sarcoma	0.00488	0.00488	CcSEcCtD
Gadoteridol—Hypertension—Mitoxantrone—sarcoma	0.00486	0.00486	CcSEcCtD
Gadoteridol—Chest pain—Mitoxantrone—sarcoma	0.00479	0.00479	CcSEcCtD
Gadoteridol—Paraesthesia—Thiotepa—sarcoma	0.00478	0.00478	CcSEcCtD
Gadoteridol—Anxiety—Mitoxantrone—sarcoma	0.00478	0.00478	CcSEcCtD
Gadoteridol—Discomfort—Mitoxantrone—sarcoma	0.00474	0.00474	CcSEcCtD
Gadoteridol—Anaphylactic shock—Vincristine—sarcoma	0.00472	0.00472	CcSEcCtD
Gadoteridol—Oedema—Vincristine—sarcoma	0.00472	0.00472	CcSEcCtD
Gadoteridol—Anaphylactic shock—Mitoxantrone—sarcoma	0.0046	0.0046	CcSEcCtD
Gadoteridol—Oedema—Mitoxantrone—sarcoma	0.0046	0.0046	CcSEcCtD
Gadoteridol—Dysgeusia—Etoposide—sarcoma	0.00459	0.00459	CcSEcCtD
Gadoteridol—Hyperhidrosis—Vincristine—sarcoma	0.00456	0.00456	CcSEcCtD
Gadoteridol—Pain—Thiotepa—sarcoma	0.00455	0.00455	CcSEcCtD
Gadoteridol—Shock—Mitoxantrone—sarcoma	0.00452	0.00452	CcSEcCtD
Gadoteridol—Pain—Dactinomycin—sarcoma	0.00452	0.00452	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Epirubicin—sarcoma	0.0045	0.0045	CcSEcCtD
Gadoteridol—Hyperhidrosis—Mitoxantrone—sarcoma	0.00444	0.00444	CcSEcCtD
Gadoteridol—Hypotension—Vincristine—sarcoma	0.00441	0.00441	CcSEcCtD
Gadoteridol—Feeling abnormal—Thiotepa—sarcoma	0.00438	0.00438	CcSEcCtD
Gadoteridol—Feeling abnormal—Dactinomycin—sarcoma	0.00435	0.00435	CcSEcCtD
Gadoteridol—Ill-defined disorder—Etoposide—sarcoma	0.00435	0.00435	CcSEcCtD
Gadoteridol—Hypotension—Mitoxantrone—sarcoma	0.00429	0.00429	CcSEcCtD
Gadoteridol—Paraesthesia—Vincristine—sarcoma	0.00424	0.00424	CcSEcCtD
Gadoteridol—Urticaria—Thiotepa—sarcoma	0.00423	0.00423	CcSEcCtD
Gadoteridol—Malaise—Etoposide—sarcoma	0.00422	0.00422	CcSEcCtD
Gadoteridol—Face oedema—Epirubicin—sarcoma	0.00421	0.00421	CcSEcCtD
Gadoteridol—Abdominal pain—Thiotepa—sarcoma	0.00421	0.00421	CcSEcCtD
Gadoteridol—Body temperature increased—Thiotepa—sarcoma	0.00421	0.00421	CcSEcCtD
Gadoteridol—Body temperature increased—Dactinomycin—sarcoma	0.00417	0.00417	CcSEcCtD
Gadoteridol—Abdominal pain—Dactinomycin—sarcoma	0.00417	0.00417	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Doxorubicin—sarcoma	0.00417	0.00417	CcSEcCtD
Gadoteridol—Cardiac arrest—Epirubicin—sarcoma	0.00414	0.00414	CcSEcCtD
Gadoteridol—Paraesthesia—Mitoxantrone—sarcoma	0.00413	0.00413	CcSEcCtD
Gadoteridol—Loss of consciousness—Etoposide—sarcoma	0.00412	0.00412	CcSEcCtD
Gadoteridol—Dyspnoea—Mitoxantrone—sarcoma	0.0041	0.0041	CcSEcCtD
Gadoteridol—Cough—Etoposide—sarcoma	0.00409	0.00409	CcSEcCtD
Gadoteridol—Convulsion—Etoposide—sarcoma	0.00406	0.00406	CcSEcCtD
Gadoteridol—Hypertension—Etoposide—sarcoma	0.00404	0.00404	CcSEcCtD
Gadoteridol—Pain—Vincristine—sarcoma	0.00403	0.00403	CcSEcCtD
Gadoteridol—Chest pain—Etoposide—sarcoma	0.00399	0.00399	CcSEcCtD
Gadoteridol—Discomfort—Etoposide—sarcoma	0.00394	0.00394	CcSEcCtD
Gadoteridol—Pain—Mitoxantrone—sarcoma	0.00393	0.00393	CcSEcCtD
Gadoteridol—Hypersensitivity—Thiotepa—sarcoma	0.00392	0.00392	CcSEcCtD
Gadoteridol—Face oedema—Doxorubicin—sarcoma	0.00389	0.00389	CcSEcCtD
Gadoteridol—Hypersensitivity—Dactinomycin—sarcoma	0.00389	0.00389	CcSEcCtD
Gadoteridol—Cardiac arrest—Doxorubicin—sarcoma	0.00384	0.00384	CcSEcCtD
Gadoteridol—Anaphylactic shock—Etoposide—sarcoma	0.00382	0.00382	CcSEcCtD
Gadoteridol—Feeling abnormal—Mitoxantrone—sarcoma	0.00379	0.00379	CcSEcCtD
Gadoteridol—Dysphagia—Epirubicin—sarcoma	0.00377	0.00377	CcSEcCtD
Gadoteridol—Pruritus—Thiotepa—sarcoma	0.00376	0.00376	CcSEcCtD
Gadoteridol—Abdominal pain—Vincristine—sarcoma	0.00373	0.00373	CcSEcCtD
Gadoteridol—Body temperature increased—Vincristine—sarcoma	0.00373	0.00373	CcSEcCtD
Gadoteridol—Hyperhidrosis—Etoposide—sarcoma	0.00369	0.00369	CcSEcCtD
Gadoteridol—Urticaria—Mitoxantrone—sarcoma	0.00365	0.00365	CcSEcCtD
Gadoteridol—Diarrhoea—Thiotepa—sarcoma	0.00364	0.00364	CcSEcCtD
Gadoteridol—Abdominal pain—Mitoxantrone—sarcoma	0.00363	0.00363	CcSEcCtD
Gadoteridol—Body temperature increased—Mitoxantrone—sarcoma	0.00363	0.00363	CcSEcCtD
Gadoteridol—Diarrhoea—Dactinomycin—sarcoma	0.00361	0.00361	CcSEcCtD
Gadoteridol—Hypotension—Etoposide—sarcoma	0.00357	0.00357	CcSEcCtD
Gadoteridol—Dizziness—Thiotepa—sarcoma	0.00352	0.00352	CcSEcCtD
Gadoteridol—Dysphagia—Doxorubicin—sarcoma	0.00349	0.00349	CcSEcCtD
Gadoteridol—Hypersensitivity—Vincristine—sarcoma	0.00348	0.00348	CcSEcCtD
Gadoteridol—Paraesthesia—Etoposide—sarcoma	0.00343	0.00343	CcSEcCtD
Gadoteridol—Dyspnoea—Etoposide—sarcoma	0.00341	0.00341	CcSEcCtD
Gadoteridol—Hypersensitivity—Mitoxantrone—sarcoma	0.00339	0.00339	CcSEcCtD
Gadoteridol—Vomiting—Thiotepa—sarcoma	0.00338	0.00338	CcSEcCtD
Gadoteridol—Vomiting—Dactinomycin—sarcoma	0.00336	0.00336	CcSEcCtD
Gadoteridol—Rash—Thiotepa—sarcoma	0.00335	0.00335	CcSEcCtD
Gadoteridol—Dermatitis—Thiotepa—sarcoma	0.00335	0.00335	CcSEcCtD
Gadoteridol—Headache—Thiotepa—sarcoma	0.00333	0.00333	CcSEcCtD
Gadoteridol—Rash—Dactinomycin—sarcoma	0.00333	0.00333	CcSEcCtD
Gadoteridol—Pain—Etoposide—sarcoma	0.00327	0.00327	CcSEcCtD
Gadoteridol—Diarrhoea—Vincristine—sarcoma	0.00323	0.00323	CcSEcCtD
Gadoteridol—Sweating—Epirubicin—sarcoma	0.00322	0.00322	CcSEcCtD
Gadoteridol—Nausea—Thiotepa—sarcoma	0.00316	0.00316	CcSEcCtD
Gadoteridol—Feeling abnormal—Etoposide—sarcoma	0.00315	0.00315	CcSEcCtD
Gadoteridol—Diarrhoea—Mitoxantrone—sarcoma	0.00314	0.00314	CcSEcCtD
Gadoteridol—Nausea—Dactinomycin—sarcoma	0.00314	0.00314	CcSEcCtD
Gadoteridol—Dizziness—Vincristine—sarcoma	0.00312	0.00312	CcSEcCtD
Gadoteridol—Bradycardia—Epirubicin—sarcoma	0.00307	0.00307	CcSEcCtD
Gadoteridol—Urticaria—Etoposide—sarcoma	0.00304	0.00304	CcSEcCtD
Gadoteridol—Rhinitis—Epirubicin—sarcoma	0.00302	0.00302	CcSEcCtD
Gadoteridol—Abdominal pain—Etoposide—sarcoma	0.00302	0.00302	CcSEcCtD
Gadoteridol—Body temperature increased—Etoposide—sarcoma	0.00302	0.00302	CcSEcCtD
Gadoteridol—Vomiting—Vincristine—sarcoma	0.003	0.003	CcSEcCtD
Gadoteridol—Sweating—Doxorubicin—sarcoma	0.00298	0.00298	CcSEcCtD
Gadoteridol—Rash—Vincristine—sarcoma	0.00297	0.00297	CcSEcCtD
Gadoteridol—Dermatitis—Vincristine—sarcoma	0.00297	0.00297	CcSEcCtD
Gadoteridol—Headache—Vincristine—sarcoma	0.00296	0.00296	CcSEcCtD
Gadoteridol—Vomiting—Mitoxantrone—sarcoma	0.00292	0.00292	CcSEcCtD
Gadoteridol—Rash—Mitoxantrone—sarcoma	0.0029	0.0029	CcSEcCtD
Gadoteridol—Dermatitis—Mitoxantrone—sarcoma	0.00289	0.00289	CcSEcCtD
Gadoteridol—Headache—Mitoxantrone—sarcoma	0.00288	0.00288	CcSEcCtD
Gadoteridol—Bradycardia—Doxorubicin—sarcoma	0.00284	0.00284	CcSEcCtD
Gadoteridol—Hypersensitivity—Etoposide—sarcoma	0.00282	0.00282	CcSEcCtD
Gadoteridol—Tinnitus—Epirubicin—sarcoma	0.00281	0.00281	CcSEcCtD
Gadoteridol—Nausea—Vincristine—sarcoma	0.0028	0.0028	CcSEcCtD
Gadoteridol—Flushing—Epirubicin—sarcoma	0.0028	0.0028	CcSEcCtD
Gadoteridol—Rhinitis—Doxorubicin—sarcoma	0.0028	0.0028	CcSEcCtD
Gadoteridol—Nausea—Mitoxantrone—sarcoma	0.00273	0.00273	CcSEcCtD
Gadoteridol—Pruritus—Etoposide—sarcoma	0.0027	0.0027	CcSEcCtD
Gadoteridol—Erythema—Epirubicin—sarcoma	0.00263	0.00263	CcSEcCtD
Gadoteridol—Diarrhoea—Etoposide—sarcoma	0.00262	0.00262	CcSEcCtD
Gadoteridol—Tinnitus—Doxorubicin—sarcoma	0.0026	0.0026	CcSEcCtD
Gadoteridol—Flushing—Doxorubicin—sarcoma	0.00259	0.00259	CcSEcCtD
Gadoteridol—Dysgeusia—Epirubicin—sarcoma	0.00257	0.00257	CcSEcCtD
Gadoteridol—Dizziness—Etoposide—sarcoma	0.00253	0.00253	CcSEcCtD
Gadoteridol—Ill-defined disorder—Epirubicin—sarcoma	0.00244	0.00244	CcSEcCtD
Gadoteridol—Vomiting—Etoposide—sarcoma	0.00243	0.00243	CcSEcCtD
Gadoteridol—Erythema—Doxorubicin—sarcoma	0.00243	0.00243	CcSEcCtD
Gadoteridol—Rash—Etoposide—sarcoma	0.00241	0.00241	CcSEcCtD
Gadoteridol—Dermatitis—Etoposide—sarcoma	0.00241	0.00241	CcSEcCtD
Gadoteridol—Headache—Etoposide—sarcoma	0.00239	0.00239	CcSEcCtD
Gadoteridol—Dysgeusia—Doxorubicin—sarcoma	0.00238	0.00238	CcSEcCtD
Gadoteridol—Malaise—Epirubicin—sarcoma	0.00237	0.00237	CcSEcCtD
Gadoteridol—Syncope—Epirubicin—sarcoma	0.00235	0.00235	CcSEcCtD
Gadoteridol—Loss of consciousness—Epirubicin—sarcoma	0.00231	0.00231	CcSEcCtD
Gadoteridol—Cough—Epirubicin—sarcoma	0.00229	0.00229	CcSEcCtD
Gadoteridol—Convulsion—Epirubicin—sarcoma	0.00227	0.00227	CcSEcCtD
Gadoteridol—Nausea—Etoposide—sarcoma	0.00227	0.00227	CcSEcCtD
Gadoteridol—Hypertension—Epirubicin—sarcoma	0.00227	0.00227	CcSEcCtD
Gadoteridol—Ill-defined disorder—Doxorubicin—sarcoma	0.00225	0.00225	CcSEcCtD
Gadoteridol—Chest pain—Epirubicin—sarcoma	0.00223	0.00223	CcSEcCtD
Gadoteridol—Anxiety—Epirubicin—sarcoma	0.00223	0.00223	CcSEcCtD
Gadoteridol—Discomfort—Epirubicin—sarcoma	0.00221	0.00221	CcSEcCtD
Gadoteridol—Malaise—Doxorubicin—sarcoma	0.00219	0.00219	CcSEcCtD
Gadoteridol—Dry mouth—Epirubicin—sarcoma	0.00219	0.00219	CcSEcCtD
Gadoteridol—Syncope—Doxorubicin—sarcoma	0.00218	0.00218	CcSEcCtD
Gadoteridol—Anaphylactic shock—Epirubicin—sarcoma	0.00214	0.00214	CcSEcCtD
Gadoteridol—Oedema—Epirubicin—sarcoma	0.00214	0.00214	CcSEcCtD
Gadoteridol—Loss of consciousness—Doxorubicin—sarcoma	0.00213	0.00213	CcSEcCtD
Gadoteridol—Cough—Doxorubicin—sarcoma	0.00212	0.00212	CcSEcCtD
Gadoteridol—Shock—Epirubicin—sarcoma	0.00211	0.00211	CcSEcCtD
Gadoteridol—Convulsion—Doxorubicin—sarcoma	0.0021	0.0021	CcSEcCtD
Gadoteridol—Hypertension—Doxorubicin—sarcoma	0.0021	0.0021	CcSEcCtD
Gadoteridol—Hyperhidrosis—Epirubicin—sarcoma	0.00207	0.00207	CcSEcCtD
Gadoteridol—Chest pain—Doxorubicin—sarcoma	0.00207	0.00207	CcSEcCtD
Gadoteridol—Anxiety—Doxorubicin—sarcoma	0.00206	0.00206	CcSEcCtD
Gadoteridol—Discomfort—Doxorubicin—sarcoma	0.00204	0.00204	CcSEcCtD
Gadoteridol—Dry mouth—Doxorubicin—sarcoma	0.00202	0.00202	CcSEcCtD
Gadoteridol—Hypotension—Epirubicin—sarcoma	0.002	0.002	CcSEcCtD
Gadoteridol—Anaphylactic shock—Doxorubicin—sarcoma	0.00198	0.00198	CcSEcCtD
Gadoteridol—Oedema—Doxorubicin—sarcoma	0.00198	0.00198	CcSEcCtD
Gadoteridol—Shock—Doxorubicin—sarcoma	0.00195	0.00195	CcSEcCtD
Gadoteridol—Paraesthesia—Epirubicin—sarcoma	0.00192	0.00192	CcSEcCtD
Gadoteridol—Hyperhidrosis—Doxorubicin—sarcoma	0.00192	0.00192	CcSEcCtD
Gadoteridol—Dyspnoea—Epirubicin—sarcoma	0.00191	0.00191	CcSEcCtD
Gadoteridol—Hypotension—Doxorubicin—sarcoma	0.00185	0.00185	CcSEcCtD
Gadoteridol—Pain—Epirubicin—sarcoma	0.00183	0.00183	CcSEcCtD
Gadoteridol—Paraesthesia—Doxorubicin—sarcoma	0.00178	0.00178	CcSEcCtD
Gadoteridol—Dyspnoea—Doxorubicin—sarcoma	0.00177	0.00177	CcSEcCtD
Gadoteridol—Feeling abnormal—Epirubicin—sarcoma	0.00177	0.00177	CcSEcCtD
Gadoteridol—Urticaria—Epirubicin—sarcoma	0.0017	0.0017	CcSEcCtD
Gadoteridol—Pain—Doxorubicin—sarcoma	0.0017	0.0017	CcSEcCtD
Gadoteridol—Body temperature increased—Epirubicin—sarcoma	0.00169	0.00169	CcSEcCtD
Gadoteridol—Abdominal pain—Epirubicin—sarcoma	0.00169	0.00169	CcSEcCtD
Gadoteridol—Feeling abnormal—Doxorubicin—sarcoma	0.00163	0.00163	CcSEcCtD
Gadoteridol—Hypersensitivity—Epirubicin—sarcoma	0.00158	0.00158	CcSEcCtD
Gadoteridol—Urticaria—Doxorubicin—sarcoma	0.00157	0.00157	CcSEcCtD
Gadoteridol—Abdominal pain—Doxorubicin—sarcoma	0.00157	0.00157	CcSEcCtD
Gadoteridol—Body temperature increased—Doxorubicin—sarcoma	0.00157	0.00157	CcSEcCtD
Gadoteridol—Pruritus—Epirubicin—sarcoma	0.00152	0.00152	CcSEcCtD
Gadoteridol—Diarrhoea—Epirubicin—sarcoma	0.00147	0.00147	CcSEcCtD
Gadoteridol—Hypersensitivity—Doxorubicin—sarcoma	0.00146	0.00146	CcSEcCtD
Gadoteridol—Dizziness—Epirubicin—sarcoma	0.00142	0.00142	CcSEcCtD
Gadoteridol—Pruritus—Doxorubicin—sarcoma	0.0014	0.0014	CcSEcCtD
Gadoteridol—Vomiting—Epirubicin—sarcoma	0.00136	0.00136	CcSEcCtD
Gadoteridol—Diarrhoea—Doxorubicin—sarcoma	0.00136	0.00136	CcSEcCtD
Gadoteridol—Rash—Epirubicin—sarcoma	0.00135	0.00135	CcSEcCtD
Gadoteridol—Dermatitis—Epirubicin—sarcoma	0.00135	0.00135	CcSEcCtD
Gadoteridol—Headache—Epirubicin—sarcoma	0.00134	0.00134	CcSEcCtD
Gadoteridol—Dizziness—Doxorubicin—sarcoma	0.00131	0.00131	CcSEcCtD
Gadoteridol—Nausea—Epirubicin—sarcoma	0.00127	0.00127	CcSEcCtD
Gadoteridol—Vomiting—Doxorubicin—sarcoma	0.00126	0.00126	CcSEcCtD
Gadoteridol—Rash—Doxorubicin—sarcoma	0.00125	0.00125	CcSEcCtD
Gadoteridol—Dermatitis—Doxorubicin—sarcoma	0.00125	0.00125	CcSEcCtD
Gadoteridol—Headache—Doxorubicin—sarcoma	0.00124	0.00124	CcSEcCtD
Gadoteridol—Nausea—Doxorubicin—sarcoma	0.00118	0.00118	CcSEcCtD
